Agile Therapeutics (AGRX) PT Raised to $5 at RBC Capital on Surprise Twirla Recommendation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Agile Therapeutics (AGRX) PT Raised to $5 at Oppenheimer
October 31, 2019 7:46 AM EDTOppenheimer analyst Leland Gershell raised the price target on Agile Therapeutics (NASDAQ: AGRX) to $5.00 (from $4.00) while maintaining an Outperform rating.
The analyst commented, "Yesterday's victorious AdComm seemingly came out of left field following Monday's FDA briefing documents that read poorly. The panel voted... More
Agile Therapeutics (AGRX) Announces FDA AdCom Votes in Favor of Twiral Approval
October 31, 2019 6:26 AM EDTAfter the close, Agile Therapeutics, Inc. (Nasdaq: AGRX) announced a positive outcome from todays meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) of the U.S. Food and Drug Administration (FDA). The BRUDAC met to discuss the Companys New Drug... More
